Tildrakizumab

Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM) . Tildrakizumab is effective against moderate to severe plaque psoriasis[1][2][3].

Product Specifications

CAS Number

[1326244-10-3]

Product Name Alternative

SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/tildrakizumab.html

Purity

99.46

Solubility

10 mM in DMSO

Smiles

[Tildrakizumab]

Molecular Weight

(144.44 kDa)

References & Citations

[1]Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173 (4) :930-9. |[2]Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13 (1) :1964420. |[3]Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476.